This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1545109708326088v1 7/6/311    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Meynard, J.-L. Articles by Girard, P.-M. Search for Related Content PubMed PubMed Citation Articles by Meynard, J.-L. Articles by Girard, P.-M. Social Bookmarking                         What's this?

Sustained Increase of HDL Cholesterol Over a 72-Week Period in HIV-Infected Patients Exposed to an Antiretroviral Regimen Including Lopinavir/Ritonavir

^* To whom correspondence should be addressed. E-mail: karine.lacombe{at}sat.aphp.fr.

	Abstract

Metabolic disorders are a major concern during antiretroviral therapy, especially for their potential to increase cardiovascular disease risk. In a multi-center, prospective study conducted in patients exposed to an antiretroviral regimen including lopinavir boosted with ritonavir (LPV/r), an early and sustained increase of HDL-cholesterol was observed over a 72- week period. This increase was positively correlated with the exposure to LPV/r during the first 24 weeks.

First published on November 17, 2008, doi:10.1177/1545109708326088

Journal of the International Association of Physicians in AIDS Care (JIAPAC) 2008;7:311.

A more recent version of this article appeared on December 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?